2021/10/05
Keio University
An international joint research group, led by Professor Koji Hase of the Keio University Faculty of Pharmacy, Professor Takanori Kanai of the Keio University School of Medicine, Professor Ikuo Kimura of the Graduate School of Biostudies at Kyoto University, and Dr. Julie M. Clarke of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) in Australia, has revealed that gut microbiota-derived acetate improves insulin resistance in hepatocytes and suppresses the onset of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) via its receptor, FFAR2/GPR43. The results of this research were published in the international academic journal "Microbiome" on September 16, 2021 (US Eastern Time).
Please see below for the full press release.